Want to see TSE:KNE full AI Analyst Report?
KNE Stock Chart & Stats
C$0.02
<C$0.01(20.00%)
At close: 4:00 PM EDT
C$0.02
<C$0.01(20.00%)
Day’s Range― - ―
52-Week RangeC$0.02 - C$0.05
Previous CloseN/A
Volume17.00K
Average Volume (3M)112.95K
Market Cap
C$5.13M
Enterprise ValueC$6.98
Total Cash (Recent Filing)C$395.06K
Total Debt (Recent Filing)C$1.92M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding205,056,560
10 Day Avg. Volume120,057
30 Day Avg. Volume112,955
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-8.69
Price to Sales (P/S)15.17
P/FCF Ratio-1.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Biofilm TechnologyKane’s proprietary biofilm-disruption technology addresses a persistent clinical and veterinary problem. The focused IP supports durable product differentiation across wound care and animal health, enabling licensing and partner-led commercialization that can sustain long-term revenue streams.
Partner-centric Commercialization ModelA partner-centric model lets Kane monetize IP through supply, licensing and collaborations, reducing capital intensity and enabling broader distribution via established partners. Structurally this can accelerate scale while limiting fixed-cost burdens and funding needs over time.
Signs Of Deleveraging And Lower Cash BurnReported reductions in debt and improved cash burn versus prior years indicate progress on financial stabilization. If sustained, lower leverage and smaller cash outflows increase runway and reduce refinancing frequency, improving chances to execute commercialization strategies.
Bears Say
Severe Revenue DeclineAn 86% TTM revenue collapse materially weakens scale and threatens unit economics. Persistent low top-line volume undermines fixed-cost absorption, partner confidence and reinvestment capacity, making a sustainable recovery dependent on durable demand or new commercial deals.
Deep Negative MarginsNegative gross profit and extreme net losses indicate products and operations are not covering direct costs. This structural unprofitability erodes equity, accelerates cash burn, and requires substantive changes to pricing, cost structure or product mix to restore sustainable margins.
Negative Equity And Funding RiskNegative shareholders’ equity reflects accumulated losses and limits financial flexibility. It increases refinancing and dilution risk, constrains access to traditional debt, and makes the company reliant on external capital - a persistent risk to ongoing operations and strategy execution.
KNE FAQ
What was Kane Biotech Inc’s price range in the past 12 months?
Kane Biotech Inc lowest stock price was C$0.02 and its highest was C$0.05 in the past 12 months.
What is Kane Biotech Inc’s market cap?
Kane Biotech Inc’s market cap is C$5.13M.
When is Kane Biotech Inc’s upcoming earnings report date?
Kane Biotech Inc’s upcoming earnings report date is Aug 27, 2026 which is in 19 days.
How were Kane Biotech Inc’s earnings last quarter?
Currently, no data Available
Is Kane Biotech Inc overvalued?
According to Wall Street analysts Kane Biotech Inc’s price is currently Overvalued.
Does Kane Biotech Inc pay dividends?
Kane Biotech Inc does not currently pay dividends.
What is Kane Biotech Inc’s EPS estimate?
Kane Biotech Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kane Biotech Inc have?
Kane Biotech Inc has 205,056,560 shares outstanding.
What happened to Kane Biotech Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kane Biotech Inc?
Currently, no hedge funds are holding shares in TSE:KNE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kane Biotech Inc
Headquartered in Winnipeg, Canada, Kane Biotech Inc. is a biotechnology firm established in 2001, focusing on the research, development, and global commercialization of innovative technologies and products engineered to prevent and remove microbial biofilms. The company's diverse portfolio features pet dental hygiene solutions marketed as StrixNB and bluestem, alongside DispersinB for both animal and human wound care. They also provide Alosera brand shampoos for dogs, cats, and horses, and Aledex for medical device coatings. Additional offerings include DermaKB scalp care products, Coactiv+ wound care items, and other specialized products under the goldstem, silkstem, and DermaKB Biofilm brand names.
Technical Analysis
―
XORTX Therapeutics Inc
―
Quest Pharmatech
―
BioVaxys Technology
―
Doseology Sciences
―